Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activated C1s is a serine protease and a key enzymatic subcomponent of the complement system protein complex 1 (C1), which initiates the classical pathway of complement activation. It plays a central role in innate immunity, inflammation, and immune complex clearance. Activated C1s cleaves complement components C4 and C2, leading to the formation of the C3 convertase. It also cleaves non-complement proteins such as MHC I, IGFBP5, LRP6, NPMI, nucleolin, HMGBI. C1s activity is regulated by C1-inhibitor (CINH). Dysregulation or genetic defects in CIS are associated with diseases such as periodontal Ehlers-Danlos syndrome (pEDS) and Hashimoto Disease.
Serine protease inhibition by C1-inhibitor (CINH)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activated Complement Component 1s subcomponent (C1s).